NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cyclerion Therapeutics, Inc. (CYCN) Stock Analysis

Cyclerion Therapeutics, Inc. (CYCN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 14, 2026

CYCN

$3.36

−$20.58 (−85.96%)

Oct 14, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CYCN with… →

CYCN Key Statistics

As of Oct 14, 2026
Trading
Open
$3.72
Previous Close
$23.94
52-Week Range
7.19–59.36
Volume
435.85K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.76
Valuation
Market Cap
$2.25M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−11.62
Financials (FY)
Revenue (FY)
$2.07M+3.70%
Net Income (FY)
−$3.53M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
668.76K
1-Year Return
−79.75%
Dividend and dates
Avg Volume
7.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 14, 2026, CYCN closed at $3.36, −79.75% over 1 year.

Cyclerion Therapeutics, Inc. (CYCN) has a market capitalization of $2.25M.

In fiscal 2025, CYCN reported revenue of $2.07M.

CYCN Stock Return by Calendar Year

Cyclerion Therapeutics, Inc. (CYCN) return since Mar 2019: what $10,000 became

1 year
$10,000 $2,025
−79.75%
5 years
$10,000 $86
−99.14%
Since Mar 2019
$10,000 $19
−99.81%

If you had invested $10,000 in Cyclerion Therapeutics, Inc. (CYCN) at the close on March 18, 2019, the earliest close on record here, it would have been worth $19 at the close on October 14, 2026: −99.81% in total, −56.21% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−62.20%
2025−60.56%
2024−3.88%
2023−74.47%
2022−61.85%
2021−43.79%
2020+12.50%
2019 (partial year)−78.24%

As of October 14, 2026.

CYCN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.07M−$3.53M−170.1%
2024$2.00M−$3.06M−152.9%
2023$0.00−$5.26M—
2022$297.00K−$44.08M−14,841.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.07M—−$4.97M−$3.53M−170.1%
2024$2.00M—−$3.63M−$3.06M−152.9%
2023$0.00—−$9.65M−$5.26M—
2022$297.00K—−$18.54M−$44.08M−14,841.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CYCN Valuation vs Biotechnology Median

Median of 608 stocks
MetricCYCNBiotechnology medianvs median
P/S ratio1.1813.300.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cyclerion Therapeutics, Inc. (CYCN) carries a market capitalisation of $2.25M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1.

The most recent close on file for CYCN is $3.36, dated October 14, 2026. That is −$20.58 (−85.96%) against the previous close. The 52-week range on file runs from $7.19 to $59.36.

Financial Health

In fiscal 2025, Cyclerion Therapeutics, Inc. reported revenue of $2.07M. Against the prior fiscal year total of $2.00M, that is a change of +3.70%. The same year closed with a net loss of $3.53M. Trailing earnings per share are −11.62.

Across the 4 fiscal years on file, revenue moves from $297.00K in 2022 to $2.07M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.18. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −79.75%. Measured over 5 years, that is −61.40% a year compounded. The reported beta is 1.76. Daily returns over the trailing 7 years annualize to a volatility of 210.02%.

Growth & Income

No dividend is on file for CYCN.

Across the complete calendar years on file, 2020 returned +12.50% and 2023 returned −74.47%. Of the 6 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −62.20%.

Peer Comparison

Cyclerion Therapeutics, Inc. (CYCN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cyclerion Therapeutics, Inc. CYCN $2.25M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cyclerion Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 14, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Visit website →